Four 20 Pharma: six strains from Paderborn and four registration codes

• Scale. 6 strains in the list, in 10 pharmaceutical positions.
• What you won’t buy elsewhere. 4 of them are supplied exclusively by this manufacturer, so a break in their supply means a lack of these strains, not another version of them.
• Portfolio profile. Limonene leads, in 2 out of 6 strains, alongside myrcene, caryophyllene, terpinolene.
• What is missing. For 1 out of 6 strains, the pedigree remains unknown and we do not add it based on name similarity.

Who is Four 20 Pharma and where does its raw material come from?

Four 20 Pharma GmbH is based in Paderborn, Germany, and in Polish trade, it appears as the entity responsible for the pharmaceutical raw material dispensed by a doctor’s prescription. On its own website, it describes itself as an importer and wholesaler of medical cannabis, working with certified suppliers, and not as a grower.

On the card of the Polish position, the responsible entity is listed as FOUR 20 PHARMA GMBH with an address at Friedrich-List-Strasse 67 in Paderborn, the form is dried flower, and the dispensing category is Rpw. The company’s website lists a GDP certificate and a GMP certificate, alongside three German permits: manufacturing under paragraph 13 of the Medicines Act, wholesale trading under paragraph 52a of the same act, and narcotic under paragraph 3 of the Narcotic Drugs Act.

The owner of the company is now Curaleaf. The majority stake was announced in August 2022 and closed a month later, and a statement from April 30, 2026, mentions the acquisition of the remaining shares and that the Four 20 brand is entering, among others, the Polish market. The same statement cites Paderborn as the place where one hundred and ten people work.

One thing could not be determined: where the material that reaches Polish positions physically grows. The company’s website speaks of the role of an importer and suppliers, while the owner’s statement calls it a producer conducting cultivation. These two descriptions cannot be reconciled without a document that neither party publishes, so the country of cultivation remains unknown here.

Which Four 20 Pharma strains reach Polish pharmacies?

Six: Frozen Lemon Mints, Gastro Pop, GMO, Gorilla Glue, Mac 1, and Masterpiece. Each corresponds to exactly one position in our pharmaceutical listing, so none is managed by this manufacturer in two parallel declarations at the same time. Four of these names have no other supplier in Poland.

The last column counts pharmaceutical positions for the entire name, across all suppliers at once, and not just for Four 20 Pharma. This manufacturer has one position for each of the six strains, so the four next to Gorilla Glue refers to the three other entities. The names in the table have their own descriptions in this cluster, to which we refer separately. The current list of what is available in pharmacies in a given month is maintained by the list of available strains, and it is there, not here, that the variable numbers can be found. The store category hemp flower includes products available without a prescription and does not contain pharmaceutical positions described in this text.

The strain name itself does not indicate the manufacturer. Gorilla Glue is managed in this listing by four entities, and Mac 1 by two, so a patient who remembers the name will receive a position from a specific supplier at the pharmacy, not a strain as a concept. The remaining four, namely Frozen Lemon Mints, Gastro Pop, GMO, and Masterpiece, appear in our data exclusively from this manufacturer. For these four, the strain name indeed indicates one source, while for the first two, it does not indicate any.

Why does one registration code cover several strains at once?

Because the code describes the declared content, not the plant. For this manufacturer, our profile data shows four codes that differ only by the number entered in the middle of the name, and one of them covers as many as four strains. The prescription therefore pertains to the registration position, not the trade name.

The registration name is Cannabis flos Four 20 Pharma and carries a numerical component, which we do not transcribe here, as it is a declared value with its own margin, not a result of measuring a batch. Under one of these codes are Frozen Lemon Mints, Gastro Pop, GMO, and Masterpiece. Two strains, GMO and Mac 1, have two different codes in our data, and Gorilla Glue also has two.

The confusion is compounded by the record in the databases. Two positions for Mac 1 assigned to this manufacturer bear the name of a completely different brand in the title, although the producer field indicates Four 20 Pharma. The title of the page in the profile database is therefore not an identifier on which a comparison can be based, and the same applies to the strain name added to the label by sellers.

The practical conclusion is one. From the registration code, it is impossible to read which of the four strains the pharmacy will provide after the prescription is filled, because from the registry’s point of view, they are variants of the same position. Anyone wanting to compare two purchases must look at the strain name added by the pharmacy, and that does not come from an official document.

How does the raw material of this manufacturer differ from that of others?

By the documentation of trade, not the plant itself. The company declares GMP and GDP certificates and German permits for manufacturing and trading, and this describes the handling of goods, not the properties of the dried flower. No open source provides the analysis result for the series introduced into Polish pharmacies.

A distinction is worth making right away, as both layers speak of different things. The good manufacturing practice certificate and the good distribution practice certificate concern the conditions of production, storage, and transport. The Polish position card adds to this the dispensing category, form, and sizes of packaging, with the smallest weighing five grams. All of these are verifiable facts in the document and do not imply anything about the composition of a specific batch.

The second layer is the manufacturer’s material. In July 2024, an American lifestyle magazine published an interview in which the company describes its own cultivation, drying on hangers, and hand trimming, and also provides one number for the terpene content in a specific batch of Gastro Pop. The interview concerns the German market and is a statement by the company about itself, so we treat it as a declaration, not as documentation of Polish positions.

The answer to the question in the header is therefore cautious. At a verifiable level, this manufacturer does not differ from others in any measurable way: it has the same trade certificates and the same dispensing category. The differences it speaks of itself have no public confirmation.

What do profile sources say about the composition of these six strains?

Rarely the same. Four out of six strains have in our data a designation indicating that two Polish services provide them with different compositions, while the remaining two are described by only one source. Not one has received a description consistent in both databases, which for the catalog of one supplier is a result in itself.

This is best seen with Masterpiece. One database lists four compounds for this strain: caryophyllene, limonene, linalool, and myrcene. The other provides one, limonene, and ends the description there. It is not about a difference in order or rounding, but about one source seeing a four-component profile, while the other sees a one-component profile for the same pharmaceutical position.

The numbers that the first of these databases assigns to individual compounds of Masterpiece sum to 59, not 100. For the other positions of this manufacturer, the same sums range from 64 to 88 and also do not reach one hundred. Since the denominator is unknown and different each time, we present the composition as a list of compounds, not as shares, because a share without a denominator looks like a measurement, which it is not.

The same goes for genetics. For all six strains, our data records discrepancies between services: one records the strain as a hybrid, the other adds indica or sativa dominance. Six out of six is not a case of a single page, but a way in which these descriptions are created.

What is known, and what is not known about the raw material of this manufacturer?

It is known who is responsible for this raw material, in which category it is dispensed, and under what codes it stands on the pharmacy shelf. However, it is not known where the material for Polish positions grows or what the analyses of individual series showed, as none of the available sources publish this data.

Little comes from the documents, but firmly. The Polish position card provides the responsible entity with a full address in Paderborn, the form, and the Rpw category and sizes of packaging. The company’s website lists trade certificates and the numbers of regulations on which it bases its permits. The owner’s stock market announcement from April 2026 closes the ownership structure. This is all that can be verified without asking the company for consent.

Separately stands what is narrative. Interviews in lifestyle magazines, descriptions of aroma, and fields with possible effects in Polish profile databases are editorial classifications, not results of research. These databases do not state where they get their lists of compounds from, and that is precisely why two of them can describe the same position differently.

However, we did not find three things: a certificate of analysis for any batch sold in Poland, information about the country of cultivation, and a description of the method used to measure terpenes. The lack of these three items is not a charge against the manufacturer, as the law does not require them to be published. It is, however, a limit to what can be honestly said about this raw material.

Why does the availability of these strains change over time?

Because the pharmaceutical catalog is not a fixed list. In our profile data, two positions of this manufacturer have a status indicating a lack of goods, while the others have a status of high availability. This state describes only the moment of data retrieval and can reverse in both directions between subsequent retrievals.

The mechanism is simple to describe. The trading permit pertains to the registration position and lasts regardless of whether the goods are currently lying in the warehouse, and delivery depends on the release of the series, transport, and control. A strain can therefore appear in the registry all the time and simultaneously disappear from the shelf for weeks, which for the patient looks like a withdrawal, although it is not. The opposite can also happen: a position returns to sale without any announcement, and the patient learns about it only at the counter.

Therefore, this text does not contain a statement that any strain is available. The current state is maintained by the list of available strains, updated separately, and the producer’s page describes what does not change from month to month: who is responsible for the raw material, how it is documented, and what is not known about it. This text is meant to be true even in six months, so it describes the market structure, not the stock status on the day of publication.

What adverse effects have been reported after using this manufacturer’s raw material?

None specifically. We did not find a summary that attributed reports to this manufacturer or any of its six strains. Polish supervision links a report to a medicinal product and a batch number, not to the trade name of the plant, so breaking down such data by individual suppliers simply does not occur.

Reports of adverse effects are collected for a medicinal product with a batch number, not for a strain name, so the following pertains to hemp flower as a group of raw materials. The most commonly reported are dry mouth, red eyes, and increased heart rate. Less frequently described are dizziness upon standing up quickly, daytime drowsiness, and temporary worsening of short-term memory, as well as anxiety increasing with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public summaries for hemp flower in Poland do not separate them by individual products.

This has one practical consequence for this particular manufacturer. Since four of its strains stand under a common registration code, even a report described by a batch number will not clearly indicate which of them the patient took. A report can be submitted by a patient, caregiver, or a person performing a medical profession, and it is received by the registration office and the responsible entity.

Frequently asked questions about Four 20 Pharma strains

Who is responsible for the Four 20 Pharma raw material sold in Polish pharmacies?

The responsible entity listed on the Polish position card is FOUR 20 PHARMA GMBH with an address in Paderborn. Since April 2026, the company has been wholly owned by Curaleaf, which previously held a majority stake in it.

How many strains of this manufacturer are included in this listing?

Six: Frozen Lemon Mints, Gastro Pop, GMO, Gorilla Glue, Mac 1, and Masterpiece. Each corresponds to exactly one pharmaceutical position, so the manufacturer does not manage any of them in two parallel declarations.

Does Four 20 Pharma grow cannabis itself?

It has not been established. The company’s own website describes it as an importer and wholesaler working with certified suppliers, while the owner’s statement from 2026 calls it a producer conducting cultivation. None of these sources indicate the country of cultivation for Polish positions.

Is the strain name alone enough to receive this raw material at the pharmacy?

No. The prescription pertains to the registration position, and the strain name is a commercial description added by industry services and pharmacies. Four strains of this manufacturer stand in our data under the same registration code.

Have analysis results for the batches of this manufacturer’s strains been published?

We did not find such a publication. Neither the company’s website nor Polish profile services provide a certificate of analysis for the batch introduced into circulation in Poland, so the declaration on the packaging remains the only number the patient sees.

Why do the composition descriptions of Masterpiece differ between services?

Because they are created on different bases. One Polish database lists four compounds for this strain, while the other provides only limonene, and neither publishes the raw analysis result on which it could rely.

Hemp flower is a pharmaceutical raw material dispensed by a doctor’s prescription in the Rpw category, and this material is for informational purposes only and does not replace medical consultation. The editorial text was prepared by the ubucha editorial team.